KR102345335B1 - Anti-stress compositon containing lepidium apetalum extracts - Google Patents
Anti-stress compositon containing lepidium apetalum extracts Download PDFInfo
- Publication number
- KR102345335B1 KR102345335B1 KR1020200128696A KR20200128696A KR102345335B1 KR 102345335 B1 KR102345335 B1 KR 102345335B1 KR 1020200128696 A KR1020200128696 A KR 1020200128696A KR 20200128696 A KR20200128696 A KR 20200128696A KR 102345335 B1 KR102345335 B1 KR 102345335B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- stress
- weight
- parts
- Prior art date
Links
- 230000002180 anti-stress Effects 0.000 title claims abstract description 46
- 239000000284 extract Substances 0.000 title claims description 91
- 241001657511 Lepidium apetalum Species 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 230000001430 anti-depressive effect Effects 0.000 claims abstract description 27
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 240000003291 Armoracia rusticana Species 0.000 claims description 15
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 15
- 241000801118 Lepidium Species 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 13
- 240000004160 Capsicum annuum Species 0.000 claims description 11
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 11
- 235000007862 Capsicum baccatum Nutrition 0.000 claims description 11
- 239000001728 capsicum frutescens Substances 0.000 claims description 11
- 244000269722 Thea sinensis Species 0.000 claims description 8
- 241000207923 Lamiaceae Species 0.000 claims description 7
- 239000003205 fragrance Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000015701 Artemisia arbuscula Nutrition 0.000 claims description 5
- 235000002657 Artemisia tridentata Nutrition 0.000 claims description 5
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 5
- 240000006891 Artemisia vulgaris Species 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 47
- 230000003078 antioxidant effect Effects 0.000 abstract description 40
- 239000003963 antioxidant agent Substances 0.000 abstract description 35
- 239000000935 antidepressant agent Substances 0.000 abstract description 25
- 229940005513 antidepressants Drugs 0.000 abstract description 25
- 229930014626 natural product Natural products 0.000 abstract description 11
- 230000002265 prevention Effects 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 2
- 230000035882 stress Effects 0.000 description 31
- 235000006708 antioxidants Nutrition 0.000 description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 18
- 239000000796 flavoring agent Substances 0.000 description 12
- 230000002195 synergetic effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000006872 improvement Effects 0.000 description 8
- 235000019629 palatability Nutrition 0.000 description 8
- 239000002304 perfume Substances 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000032683 aging Effects 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 5
- 241001164374 Calyx Species 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 5
- 108010093894 Xanthine oxidase Proteins 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241001573881 Corolla Species 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000013040 bath agent Substances 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000005607 chanvre indien Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- -1 etc.) Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 229960002163 hydrogen peroxide Drugs 0.000 description 2
- 229960004801 imipramine Drugs 0.000 description 2
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000009323 psychological health Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- WCBPJVKVIMMEQC-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 WCBPJVKVIMMEQC-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 240000003537 Ficus benghalensis Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000227166 Harrimanella hypnoides Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020400 Hostility Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000006964 Perilla frutescens var acuta Nutrition 0.000 description 1
- 240000001979 Perilla frutescens var. acuta Species 0.000 description 1
- 240000007476 Pseudomussaenda flava Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038678 Respiratory depression Diseases 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930186949 TCA Natural products 0.000 description 1
- 206010043269 Tension headache Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000008934 psychosocial wellbeing Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000378 teratogenic Toxicity 0.000 description 1
- 230000003390 teratogenic effect Effects 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q13/00—Formulations or additives for perfume preparations
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/0003—Compounds of unspecified constitution defined by the chemical reaction for their preparation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 다닥냉이 추출물을 유효성분으로 포함하는 항스트레스용 조성물에 관한 것이다. 보다 상세하게는 다닥냉이를 포함하면서 항산화 효과를 나타낼 뿐만 아니라 스트레스 저감 효과와 우울증 예방 및 개선효과를 나타낼 수 있는 천연물 기반의 항산화, 항우울 및 항스트레스용 조성물을 제공하기 위한 것이다. 또한 상기 조성물은 높은 기호성과 함께 일반식품, 기능성 식품, 기능성 향료 등으로 활용될 수 있다.The present invention relates to a composition for anti-stress comprising a horseradish extract as an active ingredient. More specifically, it is to provide a composition for antioxidant, antidepressant and antistress based on natural products, which can exhibit not only an antioxidant effect, but also a stress reducing effect and depression prevention and amelioration effect, including Hemp horseradish. In addition, the composition can be used as general food, functional food, functional flavoring, etc. with high palatability.
노화, 암, 뇌혈관 질환, 심혈관계 질환 등과 같은 질환의 원인이 자유라디칼(free radical) 또는 활성산소종(reactive oxygen species, ROS)인 것으로 인식되고 있다. 상기 활성산소종은 생물체에 침입된 병균 등에 의한 생물학적 스트레스나 지구 환경 악화에 따른 각종 환경 스트레스 등의 스트레스로 인하여 생물 유지에 필수적으로 요구되는 산소의 반응성이 높아진 산소를 의미할 수 있으며, 상기 반응성이 높은 산소는 심각한 생리적 장애 등을 유발할 수 있게 된다. 일 예로, 슈퍼옥사이드 라디칼(superoxide radical), 하이드록실 라디칼(hydroxyl radical), 과산화수소 또는 일중항산소 등이 있다.It is recognized that the cause of diseases such as aging, cancer, cerebrovascular disease, and cardiovascular disease is free radicals or reactive oxygen species (ROS). The reactive oxygen species may mean oxygen with increased reactivity of oxygen essential for maintaining living organisms due to stress such as biological stress caused by pathogens invading living organisms or various environmental stresses caused by deterioration of the global environment, and the reactivity is High oxygen can cause serious physiological disorders and the like. Examples include a superoxide radical, a hydroxyl radical, hydrogen peroxide, or singlet oxygen.
구체적으로, 상기 자유라디칼 또는 활성산소종은 세포를 파괴하거나 피부 진피층의 결합조직을 절단하거나 교차결합을 일으키므로 주름형성, 아토피성 피부염, 여드름 또는 피부암과 같은 피부 관련 질병뿐만 아니라 암, 심근경색증(myocardial infarction), 뇌졸증(stroke), 죽상동맹경화증(atherosclerosis) 등을 포함하는 심혈관계 질환, 근위축측삭경화증(amyotrophic laternal sclerosis)이나 파킨스씨 병(Parkinsion's disease, PD)과 같은 퇴행성 신경질환(chronic neurodegenerative disease)의 원인이 되는 것으로 보고되어 있다. 또한, 자유라디칼 또는 활성산소종은 인체 내에서 지질을 과산화시켜 과산화지질이라고 하는 해로운 물질을 생성할 수 있고, 상기 과산화지질은 혈관에 작용하여 동맥경화나 혈정과 같은 각종 성인병의 원인이 되는 것으로 보고되어 있다.Specifically, the free radicals or reactive oxygen species destroy cells, cut the connective tissue of the dermal layer of the skin, or cause cross-linking, so that not only skin-related diseases such as wrinkle formation, atopic dermatitis, acne or skin cancer, but also cancer, myocardial infarction ( Cardiovascular diseases including myocardial infarction, stroke, atherosclerosis, etc., and chronic neurodegenerative diseases such as amyotrophic lateral sclerosis or Parkinsion's disease (PD). It has been reported to cause neurodegenerative disease. In addition, free radicals or reactive oxygen species can peroxidize lipids in the human body to produce harmful substances called peroxidized lipids, and the peroxidized lipids act on blood vessels to cause various adult diseases such as arteriosclerosis and blood clots. has been
상기한 바와 같이, 평균수명이 증가하고 사회의 노령화가 진행되면서 노화 및 퇴행성 질환과 같은 노화와 관련된 질병에 대한 관심이 증대되고 있고, 경제성장 및 식생활의 변화 등에 따라 대사증후군이나 성인병 등에 대한 관심이 증대되고 있다. 이러한 질병에 대한 관심의 증가와 함께 상기 질병의 원인으로 보고된 자유라디칼 또는 활성산소종에 대한 관심도 증대되면서, 항산화효과를 갖는 물질에 대한 관심이 증대되고 있다.As described above, as the average lifespan increases and the aging of society progresses, interest in aging-related diseases such as aging and degenerative diseases is increasing, and due to economic growth and changes in diet, interest in metabolic syndrome or adult diseases is increasing. is increasing As interest in these diseases increases and interest in free radicals or reactive oxygen species reported as the cause of the disease also increases, interest in substances having an antioxidant effect is increasing.
생체 내에는 이러한 자유라디칼 또는 활성산소종을 제거하는 항산화체계로 슈퍼옥사이드 디스뮤타제(superoxide dismutase, SOD), 퍼옥시다제(peroxidase, POD) 또는 카탈라제(catalase, CAT) 등의 고분자 항산화 효소와 비타민 C, 비타민 E 또는 글루타치온(glutathione) 등의 항산화 물질 등이 존재한다.As an antioxidant system that removes these free radicals or reactive oxygen species in the living body, high molecular antioxidant enzymes and vitamins such as superoxide dismutase (SOD), peroxidase (POD) or catalase (CAT) Antioxidants such as C, vitamin E or glutathione are present.
그러나, 공해나 자외선 또는 상기 생물학적 스트레스를 포함하는 여러 원인 및 노화에 의해서 점차적으로 인체의 항산화체계는 정상 작동을 하지 못하게 되며, 이러한 경우 항산화 물질을 섭취함으로써 방어할 수 있도록, 활성산소종을 제거할 수 있는 물질 즉, 항산화제의 체내 공급이 요구되고 있다. 이러한 항산화제의 체내 공급요구에 따라 항산화제 또는 항산화 효과를 갖는 식품 등을 섭취하여 상기 질병을 예방 또는 치료하거나 노화를 지연시키고자 하는 노력이 증가하고 있는 실정이다.However, due to various causes and aging, including pollution, ultraviolet rays, or the biological stress, the body's antioxidant system gradually fails to function normally. A substance that can be used, that is, an antioxidant, is required to be supplied to the body. Efforts to prevent or treat the disease or delay aging by consuming antioxidants or foods having antioxidant effects are increasing according to the demand for supply of antioxidants in the body.
종래에 뛰어난 항산화력을 지닌 합성 항산화제로는 BHA(butylated hydroxyanisole), BHT(butylated hydroxytoluene) 또는 TBHQ(tertiary butylhydropuinone) 등이 보고되어 있다.Conventionally, as synthetic antioxidants with excellent antioxidant power, BHA (butylated hydroxyanisole), BHT (butylated hydroxytoluene), or TBHQ (tertiary butylhydropuinone), etc. have been reported.
그러나, 상기 합성 항산화제는 체내 흡수 물질의 일부가 독성을 지니고 있어, 기형발생인자 및 발암 물질화 될 수 있고, 간 비대증을 유발하거나 간장 중 마이크로소말 효소활성(microsomal enzyme activity)을 증가시킬 수 있어, 폐나 신장 등의 장기 조직의 병리적인 해를 유발시키는 등의 안전성 문제가 제기되고 있다.However, since some of the substances absorbed in the body are toxic, the synthetic antioxidant may become a teratogenic factor and a carcinogen, and may cause liver hypertrophy or increase microsomal enzyme activity in the liver, Safety issues such as causing pathological harm to organ tissues such as lungs and kidneys have been raised.
따라서, 근래에는 보다 인체에 안전하고, 항산화력이 뛰어난 항산화제를 개발하기 위한 많은 연구가 진행되고 있으며, 이러한 연구에 따라 도출된 천연 항산화제 즉, 천연물질로부터 수득한 항산화제에 대한 수요가 증가하고 있다.Therefore, in recent years, many studies are being conducted to develop antioxidants that are safer for the human body and have excellent antioxidant power, and the demand for natural antioxidants derived from these studies, that is, antioxidants obtained from natural substances, is increasing. are doing
한편, 세계보건기구(WHO)는 우울증이 2020년에 인류를 괴롭힐 세계 2위의 질병이 될 것이라고 전망하고 있다. 국내의 경우 건강보험심사평가원에 따르면 우울증으로 병원을 찾는 사람들은 2010년 45만 9774명에서 2011년 47만 5670명, 2012년 52만 8361명으로 증가하여 2년간 약 15%가 증가한 것으로 보고하고 있다.Meanwhile, the World Health Organization (WHO) predicts that depression will become the world's second most afflicted disease in 2020. In Korea, according to the Health Insurance Review and Assessment Service, the number of people visiting hospitals for depression increased from 459,774 in 2010 to 475,670 in 2011 and 528,361 in 2012, an increase of about 15% over two years. .
그러나 현재 임상에 사용되는 항우울제는 모두 모노아민계 신경전달물질의 작용을 강화하는 약물들인데, 신경세포의 세로토닌 재흡수, 노르에피네프린의 재흡수 등을 억제하는 물질 (SSRI, SNRI, TCAs 계열 등), 모노아민 산화효소 억제제(monoamine oxidase inhibitors)와 같이 세로토닌이나 도파민 등의 분해를 억제하는 물질 등이 그것이다.However, all antidepressants currently used in clinical practice are drugs that enhance the action of monoamine neurotransmitters, and substances that inhibit serotonin reuptake and norepinephrine reuptake in neurons (SSRI, SNRI, TCAs, etc.) , substances that inhibit the breakdown of serotonin or dopamine, such as monoamine oxidase inhibitors.
하지만, 현재 우리나라의 우울증 환자 중 약 10-25%만이 항우울제 치료를 받고 있으며, 이중 40% 가량은 부작용 등으로 인해 순응도가 떨어져 치료를 중단하는 것으로 알려져 있고, 나아가 항우울제를 복용하더라도 반응이 없는 비반응군(non-responder)이 33%에 달하는 것으로 보고되고 있다. 따라서 천연물 유래의 항우울효과가 있는 조성물에 대한 노력이 절실히 요구되는 실정이다.However, currently only about 10-25% of depressed patients in Korea are receiving antidepressant treatment, and about 40% of them are known to stop treatment due to poor compliance due to side effects. It is reported that the non-responder accounted for 33%. Therefore, there is an urgent need for efforts on a composition having an antidepressant effect derived from a natural product.
또한 스트레스는 정신건강과 관련된 대표적인 용어로서, "외부적인 자극에 의해 발생되는 유기체에게 해로운 반응 또는 변화"로 정의할 수 있다. 스트레스를 유발하는 원인과 그로 인한 인체내 생리적 변화는 다양하다. 각종 스트레스에 대응하는 신체의 반응에는 주로 부신수질 호르몬(예: catecholamines), 부신피질자극호르몬(예: adrenocorticotrophin) 및 내인성 아편양제제(opioid)(예: endorphin, enkephalin)등의 호르몬이 관여한다.In addition, as a representative term related to mental health, stress can be defined as "a reaction or change that is harmful to an organism caused by an external stimulus". The causes of stress and the physiological changes in the human body are diverse. Hormones such as adrenal medulla (eg, catecholamines), adrenocorticotropin (eg, adrenocorticotrophin) and endogenous opioids (eg, endorphin, enkephalin) are involved in the body's response to various stresses.
특히, 구속(immobilization) 스트레스에 의하여 혈장(plasma)중의 코르티코스테론의 함량은 현저히 증가하며, 부신중의 카테콜아민 생합성 효소의 활성이 증가한다. 보통 스트레스 자극이 대뇌 등의 자극을 통하여 시상하부의 부신 피질 자극 호르몬에 의하여 부신의 기능이 항진되어 무게가 증가되며, 지질감소현상이 일어나다.In particular, the content of corticosterone in plasma significantly increases due to immobilization stress, and the activity of catecholamine biosynthetic enzymes in the adrenal glands increases. Usually, the stress stimulus is stimulated by the cerebrum, etc., and the function of the adrenal gland is enhanced by the adrenocorticotropic hormone in the hypothalamus, and the weight increases, and the lipid decrease occurs.
한편 부신은 다른 스테로이드 호르몬을 분비하여 혈액내에서 콜레스테롤, 혈당, 알카라인포스포타제(alkaline phosphatase, ALP), 락테이트디하이드로게나제(lactate dehydrogenase, LDH), 아스파테이트트랜스퍼라제(aspartate aminotransferase, AST or GOT), 알라닌 트랜스(alanine aminotrasgerase, ALT or GPT) 등을 증가시키고, 부신내의 아스코르빈산(ascorbic acid)을 혈액내로 방출시킴으로서 함량을 현저히 감소시켜 이들을 스트레스의 지표로 삼고 있다.On the other hand, the adrenal gland secretes other steroid hormones in the blood for cholesterol, blood sugar, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), aspartate aminotransferase (AST or GOT) and alanine trans (alanine aminotrasgerase, ALT or GPT), etc. are increased, and ascorbic acid in the adrenal glands is released into the blood to significantly decrease the content, which is used as an indicator of stress.
벤조디아제팜(제조사: 시그마)은 대표적인 항불안제로 작용기전이 중추신경계에서 대표적 억제성 신경 전달물질인 GABA 수용체의 친화력을 증가시켜 인접한 Cl-채널을 더 자주 열어 Cl- 이온의 투과성을 상승시키는 것으로 알려져 있다. 상기 벤조디아제팜은 효과가 즉각 나타나기는 하나, 습관성과 중독성이 있고, 전문의의 치료에 따라 사용하여야 하며, 증상이 재발하거나 금단증상이 나타난다. 벤조디아제팜의은 또한 우울증, 정신이상, 조울 행동, 불안의 고조, 적대감, 광폭함 등의 부작용이 있고. 기립성저혈압, 호흡억제, 두통, 만성수면장애, 간질환 등이 나타난다고 보고되고 있다. Benzodiazepam (manufacturer: Sigma) is a representative anti-anxiety agent, and its mechanism of action is known to increase the affinity of GABA receptors, a representative inhibitory neurotransmitter in the central nervous system, to open adjacent Cl- channels more frequently to increase the permeability of Cl- ions. . Although the effect of benzodiazepam appears immediately, it is addictive and addictive, and it must be used according to the treatment of a specialist, and symptoms recur or withdrawal symptoms appear. Benzodiazepam also has side effects such as depression, psychosis, manic behavior, heightened anxiety, hostility, and rage. Orthostatic hypotension, respiratory depression, headache, chronic sleep disturbance, and liver disease have been reported.
또한, 전기 스트레스 치료에 있어서 '멘덱' 및 정신 불안 안정제로 '안신환'제제등이 가장 널리 사용되고 있는 약물로 알려져 있으나, 이들 약물은 정신이상, 조증과 울증의 반복 등의 부작용이 있다. 특히 안신환은 불안, 호흡 촉박, 가슴뜀, 놀램, 건망증, 식은땀, 잠잘 때 땀흐름, 정액의 자연배출, 가슴 아플 때에 오래전부터 지어먹던 한약이며 부작용으로는 감정의 조절이 어렵고 습관성이 있다.In addition, in the treatment of electrical stress, 'Mendek' and 'Ahn Shin-hwan' as a mental anxiety stabilizer are known as the most widely used drugs, but these drugs have side effects such as psychosis, repeated mania and depression. In particular, Shin-Hwan Ahn is an herbal medicine that has been used for a long time when anxiety, shortness of breath, chest jump, surprise, forgetfulness, cold sweat, sweat flow during sleep, natural discharge of semen, and chest pain.
상기와 같이 스트레스 치료에 있어서 합성 화합물을 이용하는 경우 많은 부작용이 발생하기 때문에 이를 감소시키기 위하여 대체 천연물 또는 천연물로부터 유래된 항우울제 또는 항스트레스제에 대한 요구가 절실한 상황이다.As described above, when synthetic compounds are used in stress treatment, there is an urgent need for alternative natural products or antidepressants or antistress agents derived from natural products to reduce these side effects.
선행문헌을 살펴보면, 한국등록특허 제0513489호에 항우울증 치료용 연자육 추출물에 대하여 개시되어 있으며, 한국공개특허 제2013-0086459호에 산조인 추출물을 유효성분으로 함유하는 속효성 우울증 예방 및 치료용 약학적 조성물이 개시되고 있다. 한편, 부작용의 문제없이 장기간 복용 또는 사용할 수 있는 천연물 기반의 항산화, 항우울 및 항스트레스 효과를 나타낼 수 있도록 하기 위하여 보다 다양한 천연물 소재에 대한 연구가 필요하다.Looking at the prior literature, Korean Patent No. 0513489 discloses a lotus root extract for antidepressant treatment, and Korean Patent Publication No. 2013-0086459 discloses a pharmaceutical composition for preventing and treating fast-acting depression containing sanjoin extract as an active ingredient. This is being disclosed. On the other hand, in order to exhibit antioxidant, antidepressant and anti-stress effects based on natural products that can be taken or used for a long time without any side effects, research on more diverse natural materials is needed.
본 발명의 목적은 다닥냉이를 포함하면서 항산화 효과를 나타낼 뿐만 아니라 스트레스 저감 효과와 우울증 예방 및 개선효과를 나타낼 수 있는 천연물 기반의 항산화, 항우울 및 항스트레스용 조성물을 제공하기 위한 것이다.It is an object of the present invention to provide a composition for antioxidant, antidepressant and anti-stress based on natural products, which can exhibit not only an antioxidant effect, but also a stress reduction effect and a depression prevention and amelioration effect, including Hemp horseradish.
본 발명의 목적은 천연물을 기반으로 부작용의 문제없이 항산화, 항우울, 항스트레스 등의 효과를 나타낼 수 있도록 하면서 장기간 복용 또는 사용할 수 있는 조성물을 제공하기 위한 것이다.It is an object of the present invention to provide a composition that can be taken or used for a long time while being able to exhibit effects such as antioxidants, antidepressants, and antistresses without any side effects based on natural products.
본 발명의 목적은 상기 조성물을 포함하는 일반 식품, 건강기능식품, 기호성 향료 등을 제공하기 위한 것이다.It is an object of the present invention to provide a general food, health functional food, palatable fragrance, etc. comprising the composition.
상기 목적을 달성하기 위하여, 본 발명의 일 실시예에 따른 항스트레스용 조성물은 다닥냉이 추출물을 포함하는 것이다.In order to achieve the above object, the composition for anti-stress according to an embodiment of the present invention includes a horseradish extract.
상기 추출물은 물, C1 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 추출 용매를 이용하여 추출되는 것이다.The extract is extracted using an extraction solvent selected from the group consisting of water, C1 to C6 lower alcohols, and mixtures thereof.
상기 조성물은 항우울 효과를 나타내는 것이다.The composition exhibits an antidepressant effect.
상기 조성물은 고춧잎 추출물, 범꼬리풀 추출물, 차즈기 추출물 및 이들의 혼합물로 이루어진 군으로부터 선택되는 천연 추출물을 더 포함하는 것이다.The composition is to further include a natural extract selected from the group consisting of red pepper leaf extract, sagebrush extract, chazugi extract, and mixtures thereof.
본 발명의 다른 일 실시예에 따른 스트레스 개선용 향료는 상기 항스트레스용 조성물을 포함하는 것일 수 있다.The perfume for improving stress according to another embodiment of the present invention may include the anti-stress composition.
본 발명의 또 다른 일 실시예에 따른 우울증 예방용 식품 조성물은 상기 항스트레스용 조성물을 포함하는 것일 수 있다.The food composition for preventing depression according to another embodiment of the present invention may include the anti-stress composition.
본 발명의 또 다른 일 실시예에 따른 우울증 예방 및 치료용 약학 조성물은 상기 항스트레스용 조성물을 포함하는 것일 수 있다.The pharmaceutical composition for preventing and treating depression according to another embodiment of the present invention may include the anti-stress composition.
이하, 본 발명을 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명의 일 실시예에 따른 항스트레스용 조성물은 다닥냉이 추출물을 포함하는 것이다.The composition for anti-stress according to an embodiment of the present invention includes a horseradish extract.
본 명세서 전체에서, '추출물'은 상술한 바와 같이 당엽계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. 즉, 추출물은 상술한 추출용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제과정을 추가적으로 적용하여 얻은 것도 포함한다. 예컨대, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 본 발명의 추출물에 포함되는 것이다.Throughout this specification, 'extract' has the meaning commonly used as a crude extract in the sugar leaf system as described above, but in a broad sense also includes a fraction obtained by additionally fractionating the extract. That is, the extract includes not only those obtained using the above-described extraction solvent, but also those obtained by additionally applying a purification process thereto. For example, a fraction obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (prepared for separation according to size, charge, hydrophobicity or affinity), etc. The fraction obtained through the purification method is also included in the extract of the present invention.
본 명세서 전체에서, 어떤 부분이 어떤 구성요소를 "포함" 한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성 요소를 더 포함할 수 있는 것을 의미한다.Throughout this specification, when a part "includes" a certain component, it means that other components may be further included, rather than excluding other components, unless otherwise stated.
본 명세서 전체에서, 마쿠시 형식의 표현에 포함된 "이들의 조합"의 용어는 마쿠시 형식의 표현에 기재된 구성 요소들로 이루어진 군에서 선택되는 하나 이상의 혼합 또는 조합을 의미하는 것으로서, 상기 구성 요소들로 이루어진 군에서 선택되는 하나 이상을 포함하는 것을 의미한다.Throughout this specification, the term "combination of these" included in the expression of the Markush form means one or more mixtures or combinations selected from the group consisting of the components described in the expression of the Markush form, and the components It is meant to include one or more selected from the group consisting of.
본 명세서 전체에서, 용어 "예방" 이란, 조성물의 투여에 의해 관절염을 억제시키거나 발병을 지연시키는 모든 행위를 의미하며, "치료" 또는 "개선"이란, 조성물의 투여에 의해 증세가 호전되거나 이롭게 변경시키는 모든 행위를 의미한다.Throughout this specification, the term "prevention" refers to any action that suppresses or delays the onset of arthritis by administration of the composition, and "treatment" or "improvement" means that the symptoms are improved or beneficial by administration of the composition Any action that changes
본 발명에서 이용되는 추출물은 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말 상태로 제조될 수 있다.The extract used in the present invention may be prepared in a powder state by an additional process such as distillation under reduced pressure and freeze-drying or spray-drying.
본 발명에서 말하는 "항산화"는 활성산소의 저감 및 세포의 산화 또는 노화를 억제하는 효과를 나타내는 것을 말한다."Antioxidant" as used in the present invention refers to exhibiting the effect of reducing active oxygen and inhibiting oxidation or aging of cells.
본 발명에서 말하는 우울증은, 우울 장애(depressive disorder)라고도 하며, 이는 의욕 저하와 우울감을 주요 증상으로 하여 다양한 인지, 정신 또는 신체적 증상을 일으켜 일상 기능의 저하를 가져오는 질환을 말한다. 한편, 본 발명에서 말하는 "항우울"이란 위 우울증 또는 우울 장애를 예방 및 개선할 수 있고, 의욕저하 및 우울감을 개선하는 효과를 말한다.Depression as used in the present invention, also called depressive disorder, refers to a disease that causes a decrease in daily functioning by causing various cognitive, mental, or physical symptoms with a decrease in motivation and depression as the main symptoms. On the other hand, "anti-depression" as used in the present invention refers to the effect of being able to prevent and improve gastric depression or depressive disorder, and to improve motivation and depression.
본 발명에서 말하는 스트레스와 관련하여 이에 대한 정의는 학자들마다 약간씩 다르지만, 스트레스는 외부 자극에 의해 발생되는 유기체에 대한 해로운 반응 또는 변화를 의미한다. 일반적으로, 생체에 미치는 자극이 일정한 정도 이상이 될 경우 상해적으로 작용하는데, 이때 생체는 그 자극의 종류에 관계없이 일정한 위협에 대한 반응으로 긴장성 두통, 편두통, 고혈압, 소화불량, 피로, 통증, 발모 및 피부의 거칠어짐 등을 일으키고, 만성적으로 지속되면 각종 신경증, 위궤양 등을 유발시키는 등의 비특이적인 전신적증후군(general adaptive syndrome)을 나타내게 되는데, 이를 스트레스라 정의하고 있다(Selye, 1958, Longmans Green and Co.). The definition of stress in the present invention is slightly different for each scholar, but stress refers to a detrimental response or change to an organism caused by an external stimulus. In general, when the stimulus on the living body exceeds a certain level, it acts invasively. At this time, the organism responds to a certain threat regardless of the type of stimulus, such as tension headache, migraine, high blood pressure, indigestion, fatigue, pain, It causes hair growth and roughness of the skin, and if it continues chronically, it results in a nonspecific general adaptive syndrome, such as various neurosis and gastric ulcer, which is defined as stress (Selye, 1958, Longmans Green). and Co.).
특히, 우울증과 같은 정신장애, 신경성위, 십이지장궤양 등과 같은 소화기장애, 스트레스성 갑상선 기능 항진증과 같은 내분비장애, 스트레스성 기미나 여드름 등과 같은 피부장애, 및 부정맥이나 협심증과 같은 심혈관계 장애 등의 다양한 질환이 스트레스로 인해 유발되는 것으로 보고되고 있다.In particular, various diseases such as mental disorders such as depression, digestive disorders such as neurosis and duodenal ulcer, endocrine disorders such as stress hyperthyroidism, skin disorders such as stress spots or acne, and cardiovascular disorders such as arrhythmias or angina pectoris It has been reported that the disease is caused by stress.
본 발명에서 말하는 "항스트레스"는 상술한 스트레스 또는 스트레스에 의한 질환을 예방 또는 개선할 수 있도록 하는 효과를 말한다."Anti-stress" as used in the present invention refers to the effect of preventing or ameliorating the aforementioned stress or diseases caused by stress.
상기 다닥냉이(Lepidium apetalum)는 배추과의 두해살이풀로, 귀화식물로 북아메리카 원산이다. 길가나 빈터 어디서나 자라는데 건조한 땅을 좋아하며 키는 30~60 센티미터 정도이다. 줄기는 곧게 서고 윗부분에서 가지가 많이 갈라져 빗자루처럼 퍼진다. 뿌리에서 난 잎은 방사상으로 퍼지며 깃꼴겹잎이다. 작은 잎은 길이 3~5 센티미터쯤 되며 잎자루가 길다. 줄기에서 나는 잎은 어긋나며 잎자루가 없고 가장자리에 톱니가 있으며 거꾸로 된 바소꼴이었다가 끝으로 갈수록 선 모양이 된다. 꽃은 5~7월에 흰색으로 피고 가지 끝과 원줄기 끝의 총상 꽃차례에 달린다. 6~7월에 영그는 열매는 길이 3 밀리미터, 너비 2 밀리미터 정도로 동글납작하고 끝이 약간 오목하게 파인다. 적갈색의 씨는 가장자리에 흰 날개를 달고 있다.The Lepidium apetalum is a biennial herb of the Brassica family, a naturalized plant, native to North America. It grows anywhere along the roadside or in a clearing, prefers dry soil, and is about 30 to 60 centimeters tall. Stems stand upright and branches are divided at the upper part and spread like a broom. The leaves from the root spread radially and are pinnate compound leaves. The small leaves are about 3-5 centimeters long and have long petioles. The leaves from the stem are alternate phyllotaxis, have no petiole, have serrations on the edge, and have an inverted lancet shape and become a line shape toward the end. White flowers bloom in May-July and hang on raceme at the end of branches and main stems. In June-July, the young fruit is about 3 mm long and 2 mm wide, round and flat, and the tip is slightly concave. The reddish-brown seeds have white wings on the edge.
본 발명의 항스트레스용 조성물은 상기 다닥냉이 추출물을 포함하는 경우 항산화 활성과 함께, 스트레스를 예방 및 완화하고 우울증을 예방 및 개선하는 효과를 나타낼 수 있다. When the composition for anti-stress of the present invention contains the extract of Lepidoptera, it can exhibit the effect of preventing and alleviating stress and preventing and ameliorating depression along with antioxidant activity.
또한 상기 항스트레스용 조성물을 통하여 스트레스에 따라 발병할 수 있는 여러 질환을 예방 및 개선하는 효과를 낼 수 있다.In addition, through the composition for anti-stress, it is possible to prevent and improve various diseases that may be caused by stress.
상기 다닥냉이 추출물은 물, C1 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 추출 용매를 이용하여 추출되는 것이다.The Lepidium extract is extracted using an extraction solvent selected from the group consisting of water, C1 to C6 lower alcohols, and mixtures thereof.
바람직하게 상기 용매는 물, 에탄올 및 이들의 혼합물로 이루어진 군에서 선택된 어느 하나일 수 있다. 상기 용매에 의하는 경우 항산화, 항스트레스 및 항우울 효과를 나타내는 유효성분에 대한 수득률에 높게 유지될 수 있어 상대적으로 적은 함량에 비하여 보다 우수한 효과를 나타낼 수 있다.Preferably, the solvent may be any one selected from the group consisting of water, ethanol, and mixtures thereof. In the case of the solvent, the yield for the active ingredient exhibiting antioxidant, anti-stress and anti-depressant effects can be maintained at a high level, and thus a more excellent effect can be exhibited compared to a relatively small content.
상기 항스트레스용 조성물은 고춧잎 추출물, 범꼬리풀 추출물, 차즈기 추출물 및 이들의 혼합물로 이루어진 군으로부터 선택되는 천연 추출물을 더 포함하는 것이다.The composition for anti-stress will further include a natural extract selected from the group consisting of red pepper leaf extract, cauliflower extract, chazugi extract, and mixtures thereof.
상기 고춧잎은 고추(hot pepper)의 잎을 말한다.The red pepper leaf refers to a leaf of hot pepper.
상기 범꼬리풀은 산골짜기 양지에서 자란며, 높이 30 내지 80cm이다. 뿌리줄기가 짧고 굵으며 잔뿌리가 많다. 뿌리에 달린 잎은 어긋나고 잎자루가 길며 넓은 달걀 모양이고 점차 좁아져서 끝이 뾰족하고 밑은 심장밑 모양이다. 잎 가장자리는 밋밋하고 뒷면은 흰빛이다. 잎 길이 5 내지 10cm, 나비 3 내지 7cm이다. 줄기에 달린 잎은 이와 비슷하지만 잎자루가 짧고 잎도 작다. 잎집은 막질(膜質: 얇은 종이처럼 반투명한 것)이다. 꽃은 6 또는 7월에 연분홍색 또는 흰색으로 피고 수상꽃차례에 달린다. 꽃잎은 없고 꽃받침은 5개로 갈라진다. 수술은 8개로 꽃받침보다 좀더 길고, 꽃밥은 연한 붉은빛을 띤 자주색이며 수술대 밑부분에 작은 샘[腺]이 있다. 열매는 수과로서 9 또는 10월에 익는데, 꽃받침에 싸이며 3개의 능선이 있다. 어린 잎과 줄기는 식용하고, 뿌리줄기는 열을 내리거나 경기(驚氣)를 다스리며 종기의 염증을 없애는 데 사용한다. 한국, 중국 동북부, 헤이룽강, 우수리강 등지에 분포한다.The pan-tailed grass grows in a sunny valley in a mountain valley, and the height is 30 to 80 cm. The rhizome is short and thick, and there are many fine roots. The leaf attached to the root is alternate phyllotaxis, the petiole is long, broad egg-shaped, gradually narrows and has a sharp tip, and the bottom is in the shape of a heart. The edge of the leaf is flat and the back side is white. Leaves are 5 to 10 cm long and 3 to 7 cm wide. The leaves on the stem are similar to this, but the petiole is short and the leaves are small. The sheath is membranous (膜質: translucent like thin paper). Flowers bloom in June or July in light pink or white, and hang on the inflorescence. There are no petals, and sepals are divided into 5 pieces. There are 8 stamens, longer than the calyx, the anthers are light reddish purple, and there is a small gland [腺] at the bottom of the stamens. Fruits are aqueous and ripen in September or October, are wrapped in calyx, and have 3 ridges. The young leaves and stems are edible, and the rhizomes are used to relieve heat, control competition, and eliminate inflammation of boils. It is distributed in Korea, northeastern China, Heilong River, and Ussuri River.
상기 차즈기(Perilla frutescens var. acuta)는 줄기는 곧게 서고 높이가 20 내지 80cm이며 단면이 사각형이고 자줏빛이 돌며 향기가 있다. 잎은 마주나고 넓은 달걀 모양이며 끝이 뾰족하고 밑 부분이 둥글며 가장자리에 톱니가 있다. 잎 양면에 털이 있고, 뒷면 맥 위에는 긴 털이 있으며, 잎자루가 길다. 꽃은 8 또는 9월에 연한 자줏빛으로 피고 줄기와 가지 끝에 총상꽃차례를 이루며 달린다. 꽃받침은 털이 있고 2개로 갈라지며, 갈라진 조각 중 위쪽 것은 다시 3개로 갈라지고 아래쪽 조각은 다시 2개로 갈라진다. 화관은 짧은 통 모양이고 끝이 입술 모양을 이루며, 아랫입술이 윗입술보다 약간 길다. 수술은 4개인데, 그 중에 2개가 길다. 열매는 분과(分果: 분열과에서 갈라진 각 열매)이고 둥글며 지름이 1.5mm이고 꽃받침 안에 들어 있다.The chazugi (Perilla frutescens var. acuta) has a straight stem, a height of 20 to 80 cm, a square cross section, a purple color, and a fragrance. The leaves are opposite, broad egg-shaped, pointed at the tip, rounded at the bottom, and serrated at the edge. There are hairs on both sides of the leaves, long hairs on the veins on the back side, and long petioles. Flowers bloom in August or September in light purple and run in raceme at the ends of stems and branches. The calyx has hairs and is split into two, and the upper part of the split pieces is split into three again, and the lower piece is split into two again. The corolla is short, cylindrical, and the tip is lip-shaped, and the lower lip is slightly longer than the upper lip. There are 4 stamens, and 2 of them are long. The fruit is a branch (separate: each fruit divided from the fissionaceae), is round, has a diameter of 1.5mm, and is contained in a calyx.
상기 고춧잎 추출물, 범꼬리풀 추출물 및 차즈기 추출물을 본 발명의 항스트레스용 조성물에 더 포함하는 경우, 항스트레스에 대한 상승효과를 나타낼 수 있다.When the red pepper leaf extract, the banyan tree extract and the chazugi extract are further included in the anti-stress composition of the present invention, a synergistic effect on anti-stress can be exhibited.
바람직하게 상기 항스트레스용 조성물은 다닥냉이 추출물을 포함하고, 상기 닥냉이 추출물 100 중량부에 대하여 고춧잎 추출물 0.1 내지 20 중량부; 범꼬리풀 5 내지 50 중량부 및 차즈기 추출물 0.1 내지 20 중량부를 포함하는 것이다.Preferably, the anti-stress composition comprises a horseradish extract, 0.1 to 20 parts by weight of a red pepper leaf extract based on 100 parts by weight of the horseradish extract; It will contain 5 to 50 parts by weight of sagebrush and 0.1 to 20 parts by weight of chazugi extract.
상기 범위에 의하는 경우, 각 추출물의 상호 작용에 의한 상승효과로 항산화, 항우울 및 항스트레스 효과가 크게 상승할 수 있다. 따라서 보다 적은 함량으로 높은 효과를 낼 수 있으며, 장기간 복용하는 경우에도 세포독성 기타 부작용의 문제가 없다.According to the above range, antioxidant, antidepressant and anti-stress effects may be significantly increased due to the synergistic effect of the interaction of each extract. Therefore, it can produce a high effect with a smaller content, and there is no problem of cytotoxicity and other side effects even when taken for a long time.
더 바람직하게 상기 항스트레스용 조성물은 꿀풀 추출물, 홍설차 추출물 및 천문동 추출물을 더 포함하는 것이다.More preferably, the anti-stress composition further comprises an extract of Lamiaceae, a red snow tea extract and an extract of Cheonmundong.
바람직하게 상기 항스트레스용 조성물은 다닥냉이 추출물을 포함하고, 상기 다닥냉이 추출물 100 중량부에 대하여 고춧잎 추출물 0.1 내지 20 중량부; 범꼬리풀 5 내지 50 중량부; 차즈기 추출물 0.1 내지 20 중량부; 꿀풀 추출물 0.1 내지 10 중량부; 홍설차 추출물 0.1 내지 10 중량부 및 천문동 추출물 0.1 내지 10 중량부를 포함하는 것이다.Preferably, the anti-stress composition comprises a Lepidium extract, 0.1 to 20 parts by weight of a red pepper leaf extract based on 100 parts by weight of the Lepidium extract; 5 to 50 parts by weight of sagebrush; 0.1 to 20 parts by weight of chazugi extract; 0.1 to 10 parts by weight of Lamiaceae extract; It will contain 0.1 to 10 parts by weight of red snow tea extract and 0.1 to 10 parts by weight of Cheonmundong extract.
상기 "꿀풀"은 전국의 산과 들에 흔하게 자라는 여러해살이풀로 중국과 일본에도 분포한다. 뿌리줄기가 있다. 줄기는 붉은색이 돌며, 털이 많고, 높이 20-60cm다. 잎은 마주나며, 난형 또는 난상 타원형, 가장자리가 밋밋하거나 톱니가 조금 있다. 꽃은 5-7월에 줄기 끝의 수상꽃차례에 빽빽이 달리며, 보라색, 분홍색, 흰색, 입술 모양이다. 꽃받침은 입술 모양, 5갈래로 갈라진다. 화관은 아랫입술이 3갈래로 갈라진다. 수술은 4개, 2개가 길다. 열매는 소견과이며, 4개로 갈라지고, 노란빛이 도는 갈색으로 익는다.The "Lamiaceae" is a perennial herb commonly grown in mountains and fields across the country, and is also distributed in China and Japan. There is a rhizome. Stems are reddish, hairy, and 20-60cm tall. The leaves are opposite, ovate or ovate oval, with a flat edge or some serrations. Flowers are densely hung on the inflorescence at the tip of the stem in May-July, and are purple, pink, white, and lip-shaped. The calyx is lip-shaped, divided into 5 parts. The lower lip of the corolla is divided into three parts. Stamens 4, 2 are long. The fruit is a soybean, split into 4, and ripens to yellowish brown.
상기 "홍설차"(Snow Tea, 紅雪茶)는 고산지대의 향나무 고목에서 자생하는 이끼류 식물을 건조한 것을 말한다.The "Snow Tea" (Snow Tea, 紅雪茶) refers to a dried moss plant that grows wild in an old juniper tree in an alpine region.
상기 "천문동"은 바닷가에서 자라며, 뿌리줄기는 짧고 양끝이 뾰족한 원기둥 모양의 많은 뿌리가 사방으로 퍼진다. 줄기의 밑부분은 달걀 모양의 비늘 조각이 있다. 줄기는 녹색으로 길이 1 내지 2m에 달하며 덩굴성이고 잎같이 생긴 가지는 1 내지 3개씩 모여 달리며 활처럼 굽는다. 꽃은 5 또는 6월에 피고 잎겨드랑이에 1 내지 3개씩 달리며 연한 황색이고 작은꽃줄기는 중앙에 관절이 있으며 꽃잎의 길이와 비슷하다. 화피갈래조각은 황백색이고 긴 타원형이다. 꽃잎과 수술은 6개씩이고 암술대는 3개이다. 열매는 장과(漿果)로 둥글고 지름 6mm 정도이며 흰빛으로 성숙하고 검은 종자가 1개 들어 있다.The "Cheonmun-dong" grows on the seashore, and the rhizome is short and many cylindrical roots with pointed ends spread in all directions. The lower part of the stem has egg-shaped scales. Stems are green, reaching 1 to 2m in length, tendrils, and leaf-like branches run in groups of 1 to 3 and bend like a bow. Flowers bloom in May or June, hang 1 to 3 in leaf axils, light yellow, and small flower stalks have joints in the center and are similar to the length of petals. Inflorescences are yellowish-white in color and have a long oval shape. There are 6 petals and 6 stamens, and 3 styles. The fruit is a berry, round, about 6mm in diameter, matured in white, and contains 1 black seed.
상기 꿀풀 추출물, 홍설차 추출물 및 천문동 추출물을 상기 범위로 더 포함하는 경우, 각 유효성분의 상호 작용으로 항산화, 항우울 및 항스트레스에 대한 추가적인 상승효과가 나타날 뿐만 아니라, 향미와 기호성이 크게 높아지는 효과를 낼 수 있다. 따라서 기호성이 우수한 식품, 향료 조성물을 널리 보급할 수 있다.When the Lamiaceae extract, red snow tea extract and Cheonmundong extract are further included in the above range, the interaction of each active ingredient not only exhibits an additional synergistic effect on antioxidant, antidepressant and antistress, but also significantly increases flavor and palatability. can pay Accordingly, it is possible to widely distribute food and fragrance compositions with excellent palatability.
본 발명의 다른 일 실시예에 따른 스트레스 개선용 향료는 상기 항스트레스용 조성물을 포함하는 것이다.A perfume for improving stress according to another embodiment of the present invention includes the anti-stress composition.
상기 향료에 대한 발명의 구현을 예시하면 본 발명의 조성물은 방향제, 디퓨져, 향초, 마사지 오일, 바디 오일, 발향 램프, 아로마스틱, 스프레이제, 비누(예컨대, 미용 비누) 및 입욕제의 형태로 구현될 수 있다.When exemplifying the embodiment of the invention for the perfume, the composition of the present invention may be implemented in the form of a perfume, a diffuser, a scented candle, a massage oil, a body oil, a fragrance lamp, an aroma stick, a spray, a soap (eg, beauty soap) and a bath agent. can
일 실시예를 예시하면 본 발명의 조성물은 향수, 입욕제 또는 방향제 제형으로 구현될 수 있고, 이 경우 본 발명의 방향제 조성물은 혼합 정유 외에 방향제 제조에 통상적으로 첨가되는 성분을 더 포함할 수 있다. 이러한 성분으로는 향료, 방부제, 안정화제, 색소, 항균제, 탈취제, 살균제 등이 있다.In one embodiment, the composition of the present invention may be embodied as a perfume, a bath agent or a perfume formulation, in which case the perfume composition of the present invention may further include components commonly added to perfume manufacturing in addition to the mixed essential oil. These ingredients include fragrances, preservatives, stabilizers, colorants, antibacterial agents, deodorants, and disinfectants.
본 발명의 다른 일 실시예에 따른 우울증 예방용 식품 조성물은 상기 항스트레스용 조성물을 포함하는 것이다.A food composition for preventing depression according to another embodiment of the present invention includes the anti-stress composition.
이때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 약 0.01 내지 15 중량%로 가할 수 있으며, 건강음료 조성물은 100 ㎖를 기준으로 약 0.01 내지 10g의 비율로 가할 수 있으나, 이에 제한되지 않는다.At this time, the amount of the extract in the food or beverage may be added in an amount of about 0.01 to 15% by weight of the total food weight, and the health drink composition may be added in a ratio of about 0.01 to 10g based on 100 ml, but is not limited thereto.
본 발명의 식품 조성물이 음료 조성물인 경우, 지시된 비율로 필수 성분으로서 상기 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제 (사카린, 아스파탐 등)를 사용할 수 있으나, 이에 제한되지 않을 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖ 당 일반적으로 약 1 내지 20g의 범위일 수 있으나, 이에 제한되지 않을 수 있다.When the food composition of the present invention is a beverage composition, there is no particular limitation on the other ingredients except for containing the extract as an essential ingredient in the indicated ratio, and it may contain various flavoring agents or natural carbohydrates as additional ingredients like conventional beverages. can Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; disaccharides such as maltose, sucrose and the like; and polysaccharides such as conventional sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those described above, natural flavoring agents (taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) may be used, but are not limited thereto. The proportion of the natural carbohydrate may be generally in the range of about 1 to 20 g per 100 ml of the composition of the present invention, but may not be limited thereto.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있으나, 이에 제한되지 않을 수 있다.In addition to the above, the composition of the present invention contains various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickeners (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts. salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, etc., but may not be limited thereto.
그 밖에 본 발명의 조성물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있고, 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 중요하지는 않지만 본 발명의 조성물 100 중량부 당 약 0.1 내지 약 20 중량부의 범위에서 선택될 수 있으나, 이에 제한되지 않는다.In addition, the composition of the present invention may contain natural fruit juice and pulp for the production of fruit juice beverages and vegetable beverages, and these components may be used independently or in combination. The proportion of these additives is not critical, but may be selected from about 0.1 to about 20 parts by weight per 100 parts by weight of the composition of the present invention, but is not limited thereto.
본 발명에서 말하는 "기능성 식품"은 건강보조의 목적으로 특정성분을 원료로 하거나 식품원료에 들어있는 특정성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품으로 건강보조식품을 포함하며, 기타, 식품성분이 갖는 생체방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품으로서, 질병의 예방 및 질병의 회복 등과 관련된 기능도 갖는 것을 모두 포함하는 것으로 한다."Functional food" as used in the present invention is a food manufactured and processed by extracting, concentrating, refining, mixing, etc., a specific ingredient as a raw material for the purpose of health supplementation, or including health supplement food. In addition, it is a food designed and processed to sufficiently exert the biological control functions of the food ingredients, such as biological defense, regulation of biological rhythm, prevention and recovery of diseases, and functions related to disease prevention and recovery from diseases. It is assumed to include all that it has.
본 발명은 다닥냉이 추출물을 유효성분으로 포함하면서 항산화 효과를 나타낼 뿐만 아니라 스트레스 저감 효과와 우울증 예방 및 개선효과를 나타낼 수 있는 천연물 기반의 항스트레스용 조성물을 제공한다.The present invention provides a composition for anti-stress based on natural products, which can exhibit not only an antioxidant effect, but also a stress-reducing effect and depression prevention and improvement effect, while containing Lepidium extract as an active ingredient.
본 발명은 천연물을 기반으로 부작용의 문제없이 항산화, 항우울 및 항스트레스 등의 효과를 나타낼 수 있도록 하면서 장기간 복용 또는 사용할 수 있는 조성물을 제공한다.The present invention provides a composition that can be taken or used for a long period of time while being able to exhibit effects such as antioxidant, antidepressant and anti-stress without the problem of side effects based on natural products.
도 1은 본 발명의 일 실시예에 따른 조성물의 항산화 효과에 관한 것이다.
도 2는 본 발명의 일 실시예에 따른 조성물의 항산화 효과에 관한 것이다.
도 3은 본 발명의 일 실시예에 따른 조성물의 항우울 효과에 관한 것이다.1 relates to the antioxidant effect of a composition according to an embodiment of the present invention.
2 is related to the antioxidant effect of the composition according to an embodiment of the present invention.
3 relates to an antidepressant effect of a composition according to an embodiment of the present invention.
이하, 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 본 발명의 실시예에 대하여 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily carry out the present invention. However, the present invention may be embodied in several different forms and is not limited to the embodiments described herein.
[제조예: 식물 추출물의 제조][Preparation Example: Preparation of plant extract]
1. 다닥냉이 추출물의 제조1. Preparation of Lepidium extract
동결건조된 다닥냉이를 3g을 15ml 튜브(tube)에 1mg을 넣고, 70% 에탄올(ethanol)을 10ml를 다시 넣어준다. 시료를 rounded mixed machine에서 18시간동안 넣고 혼합, 추출한다. 추출 후 3000rpm, 10분 원심분리 후 상층액만 채취한다. 이렇게 채취된 상층액에 포함된 에탄올(ethanol)을 40 고온에서 증발시킨다. 그리고 남은 시료는 동결건조 시켜두었다. 본 실험에 사용한 다닥냉이 추출물(LME)은 다닥냉이의 원재료에서 수득률은 10.5%로 추출되었다.Put 3 g of lyophilized horseradish into a 15 ml tube, 1 mg, and put 10 ml of 70% ethanol again. Put the sample in a rounded mixed machine for 18 hours, mix and extract. After extraction, after centrifugation at 3000 rpm for 10 minutes, only the supernatant is collected. Ethanol contained in the supernatant collected in this way was 40 Evaporate at high temperature. And the remaining sample was freeze-dried. Lepidium extract (LME) used in this experiment was extracted from the raw material of horseradish with a yield of 10.5%.
2. 기타 식물 추출물의 제조2. Preparation of other plant extracts
고춧잎 추출물(AE)은 건조 및 분쇄된 고춧잎을 70% 에탄올(ethanol)로 추출하여 제조하였다. 또한 범꼬리풀 추출물(BE), 차즈기 추출물(CE), 꿀풀 추출물(DE), 홍설차 추출물(EE) 및 천문동 추출물(FE) 역시 위와 동일한 방법으로 제조하였다. Red pepper leaf extract (AE) was prepared by extracting dried and pulverized red pepper leaves with 70% ethanol (ethanol). In addition, the extract (BE), chrysanthemum extract (CE), Lamiaceae extract (DE), red snow tea extract (EE) and Cheonmundong extract (FE) were also prepared in the same manner as above.
3. 복합 추출물의 제조3. Preparation of Complex Extracts
각 추출물의 혼합에 따른 상승효과를 확인하기 위하여 하기의 [표 1]과 같은 조성에 따라 각 추출물을 혼합하여 복합 추출물을 제조하였다.In order to confirm the synergistic effect of mixing each extract, each extract was mixed according to the composition shown in Table 1 below to prepare a complex extract.
(단위: 중량부)(Unit: parts by weight)
[실험예: 항산화, 항우울, 항스트레스 테스트][Experimental example: antioxidant, antidepressant, anti-stress test]
1. 동물 실험방법 및 동물 그룹1. Animal test methods and animal groups
(1) 동물 실험 방법(1) Animal testing method
체중 100 내지 120 g인 4주령 Spraque-Dawley 흰쥐(한국중앙동물, 경기도, 한국)을 암컷 30마리를 구입하여 사육실 온도는 20±2 , 습도는 55-60 %를 유지하여 사육하였다. 주간-야간 주기는 12시간으로 조절하였다. 일반배합사료(PMI Nutrition LLC. Manufactured in the USA. 5L79) 및 음수는 제한을 두지 않았고 일주일간 사육실 환경에 적응기를 가진 후 실험을 실시하였다. 실험은 모두 주간에 실시하였다.Four-week-old Spraque-Dawley rats with a body weight of 100 to 120 g (Korea Central Animal, Gyeonggi-do, Korea) were purchased from 30 females and the room temperature was 20±2. , the humidity was maintained at 55-60% for breeding. The day-night cycle was adjusted to 12 hours. There were no restrictions on general formula feed (PMI Nutrition LLC. Manufactured in the USA. 5L79) and drinking water, and the experiment was conducted after a period of adaptation to the breeding room environment for a week. All experiments were conducted during the day.
(2) 동물 그룹(2) group of animals
그룹당 5마리씩 3그룹으로 나누어 진행하였다. 1그룹은 control은 구강으로 물을 투여한 그룹이며 2그룹은 시판중인 항우울제제 (Imipramine: 0.178mg/kg(rat weigh))를 투여한 그룹이고 3그룹은 다닥냉이는 15mg/150g(rat weigh)를 경구 투여하였다.5 animals per group were divided into 3 groups. Group 1 is a control group administered with water orally, group 2 is a group administered with a commercially available antidepressant (Imipramine: 0.178 mg/kg (rat weigh)), and group 3 is a group administered with horseradish 15 mg/150 g (rat weigh). was orally administered.
2. 항산화 테스트2. Antioxidant test
(1) DPPH 라디칼 소거 활성 측정 - 다닥냉이 보유 항산화(1) Measurement of DPPH radical scavenging activity - Antioxidant possessed by horseradish
DPPH (2,2-diphenyl-1-picrylhydrazyl) DPPH (2,2-diphenyl-1-picrylhydrazyl)
본 실험에 사용된 DPPH(Diphenylpicryl hydrazyl)의 hydrazyl은 질소원자가 불안정한 상태에 있으므로 쉽게 수소원자를 받아들이는 성질을 가지고 있어 항산화성 물질과 반응하여 수소원자를 받아들임으로써 자체의 정색성을 잃는 것을 이용하였다. 다닥냉이 물질별 농축 건조물을 0.05, 0.1, 0.2, 0.5, 1 mg/ml 5가지 농도로 조제한 용액 0.1 ml(control: 99.5% ethanol)에 0.2 mM DPPH용액(99.5% ethanol) 1.9 ml를 가하였다. Vortex mixer로 10초간 진탕한 후 37 에서 30분 동안 incubation시켰다. 이후 spectrophotometer를 이용하여 517 nm에서 흡광도를 측정하였다.The hydrazyl of DPPH (Diphenylpicryl hydrazyl) used in this experiment has the property of easily accepting hydrogen atoms because the nitrogen atom is in an unstable state. 1.9 ml of 0.2 mM DPPH solution (99.5% ethanol) was added to 0.1 ml (control: 99.5% ethanol) of a solution prepared in 5 concentrations of 0.05, 0.1, 0.2, 0.5, and 1 mg/ml of dried horseradish for each material. After shaking for 10 seconds with a vortex mixer, 37 incubated for 30 min. Then, the absorbance was measured at 517 nm using a spectrophotometer.
양성 대조 약물로는 L-ascorbic acid를 0.05, 0.1, 0.5, 1 mg/ml(99.5% ethanol)의 5가지 농도로 조제하여 측정하였다. 각 시료의 항산화작용은 DPPH에 대한 % Antioxidant activity (Electron donating ability)으로 나타내었다. As a positive control drug, L-ascorbic acid was prepared at 5 concentrations of 0.05, 0.1, 0.5, and 1 mg/ml (99.5% ethanol) and measured. The antioxidant activity of each sample was expressed as % Antioxidant activity (electron donating ability) against DPPH.
그 결과를 하기의 [도 1]에 나타내었다.The results are shown in [Fig. 1] below.
(2) Xanthine oxidase 저해활성 측정(2) Xanthine oxidase inhibitory activity measurement
시료용액 0.1 ml와 pH 7.5의 0.1 M potassium phosphate buffer 0.6 ml에 2 mM xanthine을 녹인 기질액 0.2 ml를 첨가하고 0.2 unit/ml xanthine oxidase 0.1ml를 가하여 37에서 5분간 반응시킨 후 1 N HCl 1 ml를 가하여 반응을 종료시킨 다음, 반응액 중에 생성된 uric acid를 292 nm에서 흡광도를 측정하였다. Xanthin oxidase저해 활성은 시료용액의 첨가군과 무첨가군의 흡광도 감소율로 나타내었다.To 0.1 ml of sample solution and 0.6 ml of 0.1 M potassium phosphate buffer of pH 7.5, 0.2 ml of substrate solution in which 2 mM xanthine was dissolved was added, and 0.2 unit/ml xanthine oxidase 0.1ml was added to 37 After reacting for 5 minutes, 1 ml of 1 N HCl was added to terminate the reaction, and the absorbance of uric acid generated in the reaction solution was measured at 292 nm. Xanthin oxidase inhibitory activity was expressed as a decrease in absorbance in the group with and without the sample solution.
Xanthine oxidase는 모든 purine의 terminal oxidation에서 rate-limiting enzyme으로 작용하며 superoxide radical이나 hydrogenperoxide와 같은 산화제의 source로서 작용하는 효소이다. Xanthine/ xanthine oxidase의 효소에 의한 superoxide음이온 저해작용은 superoxide 음이온 소거작용과 xanthine oxidase 효소 저해에 의해 나타나며 free radical의 생성 억제를 통해 생물학적으로 중요한 의미를 갖는다. 양성 대조군으로 allopurinol 50μM의 superoxide radical 소거효과를 비교하였다.Xanthine oxidase is an enzyme that acts as a rate-limiting enzyme in the terminal oxidation of all purines and as a source of oxidizing agents such as superoxide radicals and hydrogenperoxide. The inhibition of superoxide anion by the enzyme of xanthine/xanthine oxidase is indicated by the scavenging action of superoxide anion and inhibition of the xanthine oxidase enzyme, and has a biological significance by inhibiting the generation of free radicals. The superoxide radical scavenging effect of 50 μM of allopurinol as a positive control was compared.
그 결과는 하기의 [도 2]에 나타내었다. 한편, 하기의 [도 2]를 참조하면 양성대조군인 allopurinol 50μM보다 1mg/ml에서 약 18%정도 높은 소거 효과를 나타낸다는 점을 알 수 있다.The results are shown in [Fig. 2] below. On the other hand, referring to [Fig. 2] below, it can be seen that the clearing effect is about 18% higher at 1 mg/ml than the positive control,
3. 항우울 행동 실험(강제수영실험군, Forced Swiming Test, FST)3. Antidepressant behavior test (Forced Swimming Test, FST)
실험동물의 사육장에 도착 후 14일간 사육장 환경에 적응시키고 물에 적응 시키기위해 강제수영시험을 15분간 3그룹 모두 실시하여 적응시켰고 3일간 그룹별로 물(Control), 다닥냉이 추출물(LME) 그리고 항우울제(Imipramine)를 경구 복용시켰다. 강제수영실험 5분간 빠뜨린 후 초기에는 적극적으로 탈출하려는 모습이 보이나 곧 수면공포에 빠져 우울증의 정도에 따라 부동자세(immobility)를 유지하므로 부동시간을 측정하였다. 해당 실험을 3회 반복하였다.After the animals arrived at the kennel, they were acclimatized to the kennel environment for 14 days and acclimatized by conducting a forced swimming test for 15 minutes in all 3 groups to acclimatise to the water. Imipramine) was administered orally. After missing 5 minutes of the forced swimming test, it appears that they are actively trying to escape at the beginning, but they soon fall into a sleep fear and maintain an immobility according to the degree of depression, so immobility time was measured. The experiment was repeated 3 times.
한편, 그 결과를 하기의 [도 3]에 나타내었다.On the other hand, the results are shown in [Fig. 3] below.
4. 스트레스 개선효과 실험4. Stress improvement effect test
본 실험에 동의한 남녀 10명을 위약을 섭취한 대조군(placebo), 다닥냉이 추출물(LME)을 섭취한 실험군으로 각 5명씩 임의로 분류하여 4주간 각각의 차음료 형태로 400 mg씩 섭취하도록 하였다. 심리적 건강 개선효과를 살펴보기 위해, 사회, 심리적 건강측정검사인 PWI (Psychosocial Well-being Index)를 섭취 전후에 실시하였다. 객관적인 비교를 위하여 대조군의 값을 10으로 고정하고, 10점 척도로 지수를 변환하여 1 내지 10의 지수로 평가하여 그 결과를 하기의 [표 2]에 나타내었다. 하기의 지수는 그 숫자가 낮을수록 스트레스 개선효과가 우수한 것이다.Ten men and women who consented to this experiment were randomly divided into a control group (placebo) who took a placebo and an experimental group who took Lepidium extract (LME), each of which was arbitrarily divided into 5 people each, and consumed 400 mg each in the form of a tea drink for 4 weeks. In order to examine the psychological health improvement effect, PWI (Psychosocial Well-being Index), a social and psychological health measurement test, was conducted before and after intake. For objective comparison, the value of the control group was fixed at 10, the index was converted on a 10-point scale, and the index was evaluated as an index of 1 to 10, and the results are shown in [Table 2] below. In the following index, the lower the number, the better the stress improvement effect.
(단위: 지수)(Unit: Index)
상기 [표 2]를 참조하면, 본 발명에 따른 다닥냉이 추출물을 지속적으로 사용하는 경우 스트레스 완화에 도움이 될 수 있다는 것을 알 수 있다. 특히 상기 PWI 지수에 따라 자신감 상승 및 심신의 안정감이 높아질 수 있다는 점을 알 수 있다. 따라서 상기 다닥냉이 추출물을 지속적으로 사용하는 경우 스트레스를 완화할 수 있으며, 스트레스에 의하여 발병하는 질병에 대한 예방 및 개선효과를 나타내게 할 수 있다.Referring to [Table 2], it can be seen that the continuous use of the Lepidium extract according to the present invention can help relieve stress. In particular, it can be seen that self-confidence and mental and physical stability can be increased according to the PWI index. Therefore, when the horseradish extract is continuously used, stress can be alleviated, and the prevention and improvement effects of diseases caused by stress can be exhibited.
4. 복합 추출물에 대한 항산화, 항우울, 항스트레스 테스트4. Antioxidant, antidepressant, anti-stress test for complex extracts
상기와 동일한 방법으로 복합추출물 MX1 내지 MX9에 대한 항산화(AO), 항우울(AP), 항스트레스(AS) 효과를 평가하였다. 또한 다닥냉이 추출물(LME)에 비하여 상승효과가 나타나는지 확인하기 위하여, LME를 고정 값으로 하고, MX1 내지 MX9에 대한 활성을 비교하였다. Antioxidant (AO), antidepressant (AP), and antistress (AS) effects were evaluated for the complex extracts MX1 to MX9 in the same manner as above. In addition, in order to check whether a synergistic effect compared to Lepidium extract (LME), LME was set as a fixed value, and the activities of MX1 to MX9 were compared.
따라서 객관적인 비교를 위하여 하기의 평가지수는 AO 및 AP의 경우 LME 결과를 1로 고정하고, 및 MX1 내지 MX9의 값을 LME과 비교하여 1 내지 10의 지수로 변환하여 나타내었다. 상기 지수에서 AO 및 AP는 그 숫자가 높을수록 효과가 우수한 것이다. 한편, AO 및 AP에서 1로 1 미만으로 계산되는 지수도 1로 표기하였다. 따라서 AO 및 AP에서 1로 표기되는 지수는 상승효과가 없거나, LME 단독 사용보다 그 효과가 떨어지는 것이다.Therefore, for objective comparison, the following evaluation indices are shown by fixing the LME result to 1 for AO and AP, and converting the values of MX1 to MX9 into indices of 1 to 10 compared to the LME. AO and AP in the above index, the higher the number, the better the effect. On the other hand, in AO and AP, the index calculated as 1 and less than 1 is also indicated as 1. Therefore, the index indicated by 1 in AO and AP does not have a synergistic effect, or its effect is inferior to that of using LME alone.
또한, AS의 경우 LME의 결과를 10으로 고정하고, 및 MX1 내지 MX9의 값을 LME과 비교하여 1 내지 10의 지수로 변환하여 나타내었다. 상기 지수에서 AS는 그 숫자가 낮을수록 효과가 우수한 것이다. 한편, AS에서 1로 10을 초과하는 것으로 계산되는 지수도 10로 표기하였다. 따라서 AS에서 10으로 표기되는 지수는 상승효과가 없거나, LME 단독 사용보다 그 효과가 떨어지는 것이다.In addition, in the case of AS, the result of LME was fixed to 10, and the values of MX1 to MX9 were compared with LME and converted into an exponent of 1 to 10. In the above index, AS is the lower the number, the better the effect. On the other hand, the index calculated to exceed 10 by 1 in AS is also denoted as 10. Therefore, the index expressed as 10 in AS does not have a synergistic effect or has a lower effect than the use of LME alone.
그 결과를 하기의 [표 3]에 나타내었다.The results are shown in [Table 3] below.
(단위: 지수)(Unit: Index)
상기 [표 3]을 참조하면, MX1의 경우 복합 추출물에 대한 상승효과가 없었으며, MX5의 경우 LME 이외의 다른 추출물의 상대적으로 증가하면서 유의미한 상승효과가 없으며, 일부 지수는 LME 보다 낮아지는 것을 확인할 수 있었다.Referring to [Table 3], in the case of MX1, there was no synergistic effect on the complex extract, and in the case of MX5, there was no significant synergistic effect while relatively increasing other extracts other than LME, and it was confirmed that some indices were lower than LME. could
다만 MX2 내지 MX4와 같이 고춧잎 추출물, 범꼬리풀 추출물 및 차즈기 추출물이 특정 함량범위로 포함되는 실시예에 의하는 경우 각 추출물에 포함된 활성성분의 상호 조합으로 다닥냉이 추출물을 단독으로 사용하는 경우에 비하여 상승효과를 나타낸다는 것을 알 수 있다. 또한 MX3의 경우 항산화 활성, 항우울 활성 및 항스트레스 활성이 크게 향상되는 것을 알 수 있었다.However, as in MX2 to MX4, according to the embodiment in which the red pepper leaf extract, the sagebrush extract and the chazugi extract are included in a specific content range, when using the Lepidium extract alone as a mutual combination of the active ingredients included in each extract It can be seen that there is a synergistic effect. In addition, in the case of MX3, it was found that antioxidant activity, antidepressant activity and antistress activity were significantly improved.
한편, MX7 및 MX8에 의하는 경우 추가적인 상승효과를 나타낼 수 있다는 점을 확인할 수 있다. 따라서 MX7 및 MX8에 의하는 경우 보다 적은 함량으로 매우 뛰어난 항산화 활성, 항우울 활성 및 항스트레스 활성을 나타낼 수 있고, 장기간 지속적인 복용 또는 사용이 가능하다는 점을 확인할 수 있다.On the other hand, it can be confirmed that in the case of MX7 and MX8, an additional synergistic effect can be exhibited. Therefore, it can be confirmed that, in the case of MX7 and MX8, very excellent antioxidant activity, antidepressant activity and antistress activity can be exhibited with a smaller content, and continuous administration or use for a long period of time is possible.
5. 기호성 테스트5. palatability test
상기 다닥냉이 추출물(LME) 및 MX1 내지 MX9을 차형태로 가공하여 각 시음자에게 향미와 맛을 기초로 한 기호도를 평가하도록 하였다. 시음자는 위 스트레스 완화효과를 평가한 10인이 다닥냉이 추출물에 대한 기호도와 비교하여 MX1 내지 MX9의 기호성을 1 내지 10의 지수로 평가하도록 하였다. 평가된 결과 값을 평균으로 하여 하기의 [표 4]에 나타내었다. 하기의 평가 값은 소수점을 반올림하였으며, 숫자가 높을수록 기호성이 우수한 것이다.The Lepidium extract (LME) and MX1 to MX9 were processed into a tea form, and each taster was asked to evaluate the preference based on flavor and taste. The tasters were asked to evaluate the palatability of MX1 to MX9 on an index of 1 to 10 by comparing them with the palatability of the Lepidium extract by 10 people who evaluated the gastric stress relieving effect. The evaluated result values were taken as an average and are shown in [Table 4] below. The following evaluation values were rounded off with a decimal point, and the higher the number, the better the palatability.
(단위: 지수)(Unit: Index)
상기 [표 4]를 참조하면, MX1 내지 MX5에 의하는 경우 LME에 비하여 유사하거나 낮은 정도의 기호성이 나타난다는 점을 알 수 있다. 한편, MX7 내지 MX9에 의하는 경우 향미와 맛이 개선되는 효과가 나타나는 점을 알 수 있는데, 특히 MX7 및 MX8의 향미와 맛의 개선정도가 우수하다.Referring to [Table 4], it can be seen that in the case of MX1 to MX5, a similar or lower degree of palatability compared to LME appears. On the other hand, in the case of MX7 to MX9, it can be seen that the effect of improving flavor and taste appears, and in particular, the degree of improvement in flavor and taste of MX7 and MX8 is excellent.
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.Although preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements by those skilled in the art using the basic concept of the present invention as defined in the following claims are also provided. is within the scope of the
Claims (7)
고춧잎 추출물, 범꼬리풀 추출물, 차즈기 추출물, 꿀풀 추출물, 홍설차 추출물 및 천문동 추출물을 더 포함하는 것으로,
상기 다닥냉이 추출물 100 중량부에 대하여 고춧잎 추출물 0.1 내지 20 중량부, 범꼬리풀 추출물 5 내지 50 중량부, 차즈기 추출물 0.1 내지 20 중량부, 꿀풀 추출물 0.1 내지 10 중량부, 홍설차 추출물 0.1 내지 10 중량부 및 천문동 추출물 0.1 내지 10 중량부를 포함하는
항스트레스용 조성물.Contains horseradish extract as an active ingredient,
As to further include red pepper leaf extract, sagebrush extract, chazugi extract, Lamiaceae extract, red snow tea extract and cheonmundong extract,
Based on 100 parts by weight of the Lepidium extract, 0.1 to 20 parts by weight of a red pepper leaf extract, 5 to 50 parts by weight of an extract, 0.1 to 20 parts by weight of an extract, 0.1 to 10 parts by weight of an extract of Lamiaceae, 0.1 to 10 parts by weight of a red snow tea extract and 0.1 to 10 parts by weight of Cheonmundong extract
A composition for antistress.
상기 다닥냉이 추출물은 물, C1 내지 C6의 저급 알코올 및 이들의 혼합물로 이루어진 군으로부터 선택되는 추출 용매를 이용하여 추출되는 것인
항스트레스용 조성물.The method of claim 1,
wherein the horseradish extract is extracted using an extraction solvent selected from the group consisting of water, C1 to C6 lower alcohols, and mixtures thereof.
A composition for antistress.
상기 조성물은 항우울 효과를 나타내는 것인
항스트레스용 조성물.The method of claim 1,
That the composition exhibits an antidepressant effect
A composition for antistress.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200128696A KR102345335B1 (en) | 2020-10-06 | 2020-10-06 | Anti-stress compositon containing lepidium apetalum extracts |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200128696A KR102345335B1 (en) | 2020-10-06 | 2020-10-06 | Anti-stress compositon containing lepidium apetalum extracts |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102345335B1 true KR102345335B1 (en) | 2021-12-29 |
Family
ID=79176523
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200128696A KR102345335B1 (en) | 2020-10-06 | 2020-10-06 | Anti-stress compositon containing lepidium apetalum extracts |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102345335B1 (en) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100513489B1 (en) | 2002-04-01 | 2005-09-09 | 퓨리메드 주식회사 | Extract of Nelumbinis Semen for the treatment of depression |
KR20100091302A (en) * | 2009-02-10 | 2010-08-19 | (주)더페이스샵 | Cosmetic composition for whitening |
KR101049493B1 (en) * | 2010-09-17 | 2011-07-15 | 한국식품연구원 | Compositions for improving memory power and learning ability comprising extract from lepidium apefalum as active ingredient |
KR20130086459A (en) | 2012-01-25 | 2013-08-02 | 경희대학교 산학협력단 | Pharmaceutical composition for rapid acting prevention and treatment of depression comprising extract of zizyphus spinosa semen as an active ingredient |
JP2014005403A (en) * | 2012-06-26 | 2014-01-16 | Wamiles Cosmetics Kk | Perfume composition and cosmetics |
CN104397709A (en) * | 2014-12-12 | 2015-03-11 | 香格里拉县天丽斯生物科技发展有限公司 | Anti-fatigue composition |
CN107468848A (en) * | 2017-08-26 | 2017-12-15 | 青岛信诺邦生物科技有限公司 | It is a kind of treat poultry transporting stress herbal medicine material and preparation method thereof |
-
2020
- 2020-10-06 KR KR1020200128696A patent/KR102345335B1/en active IP Right Grant
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100513489B1 (en) | 2002-04-01 | 2005-09-09 | 퓨리메드 주식회사 | Extract of Nelumbinis Semen for the treatment of depression |
KR20100091302A (en) * | 2009-02-10 | 2010-08-19 | (주)더페이스샵 | Cosmetic composition for whitening |
KR101049493B1 (en) * | 2010-09-17 | 2011-07-15 | 한국식품연구원 | Compositions for improving memory power and learning ability comprising extract from lepidium apefalum as active ingredient |
KR20130086459A (en) | 2012-01-25 | 2013-08-02 | 경희대학교 산학협력단 | Pharmaceutical composition for rapid acting prevention and treatment of depression comprising extract of zizyphus spinosa semen as an active ingredient |
JP2014005403A (en) * | 2012-06-26 | 2014-01-16 | Wamiles Cosmetics Kk | Perfume composition and cosmetics |
CN104397709A (en) * | 2014-12-12 | 2015-03-11 | 香格里拉县天丽斯生物科技发展有限公司 | Anti-fatigue composition |
CN107468848A (en) * | 2017-08-26 | 2017-12-15 | 青岛信诺邦生物科技有限公司 | It is a kind of treat poultry transporting stress herbal medicine material and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8496977B2 (en) | Natural extract from whole banana fruit (Musa Spp) | |
JP6929954B2 (en) | Method for improving gingival inflammation and periodontitis by antibacterial, antioxidant, anti-inflammatory, suppression and regeneration of alveolar bone loss of Moringa leaf extract and Tochu extract complex | |
Duranova et al. | Chili peppers (Capsicum spp.): The spice not only for cuisine purposes: An update on current knowledge | |
JP5940347B2 (en) | Preventive or ameliorating agent for overactive bladder | |
KR101407659B1 (en) | A composition for inhibiting testosterone 5-alpha reductase | |
KR102093990B1 (en) | Comppsition comprising mori folium extracts for preventing, treating muscular dystrophy | |
KR20150057333A (en) | Composition comprising extract of korean fir for preventing and improving obesity | |
KR20160081205A (en) | Composition comprising extract of hydrangea serrata for preventing and improving obesity | |
JP2023118853A (en) | Anti-aging composition, anti-aging skin cosmetics and anti-aging food and drink | |
KR102345335B1 (en) | Anti-stress compositon containing lepidium apetalum extracts | |
KR102309180B1 (en) | For antioxidant, antidepressant and antistress compositions comprising maca | |
Ali et al. | Quality of guava whey beverage fortified with Moringa oleifera leaves extract | |
JP2008050301A (en) | Pancreatic lipase inhibitor | |
KR102533832B1 (en) | Functional food composition excellent in improving depression and relieving stress index | |
KR102319382B1 (en) | For antioxidant, antidepressant and antistress compositions comprising boswellia | |
KR102319379B1 (en) | Composition comprising banana leaf extract for antioxidant, antidepressant and antistress | |
KR102414267B1 (en) | For antioxidant, antidepressant and antistress compositions comprising citrus unshiu peel extract | |
KR102537835B1 (en) | Composition comprising fraxinus rhynchophylla extract for antidepressant and antistress | |
KR20180075327A (en) | Aronia jam composition with antioxidant activity and manufacturing method the same | |
KR102496534B1 (en) | Functional food composition containing olive tree extract with excellent antioxidant activity as an active ingredient | |
Lim | Lepidium meyenii | |
Santoso | Platostoma palustre (Blume) AJ Paton Lamiaceae | |
KR101632698B1 (en) | Composition for Improving Exercise Ability comprising Extract from Canavalia gladiata | |
KR20200142768A (en) | Composition for hangover cure conprising oriental herbal extract | |
KR20190120860A (en) | Cosmetic compostion including extracts of fig leaves |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |